DAYA is not just another biotech company merely interested in introducing new medicines; rather, we are dedicated to drug discovery with care.  We care for the investors who entrust us with their expectations to create wealth; we care for the patients who place their trust on us for their safety and quality of life; and we care for the scientific community who trust us to conduct research with integrity and with concern for the environment.

DAYA was founded in August 2006 in Cleveland, Ohio, but moved its operations to St. Louis in March 2007.  The Company is currently located in Benton Hall, University of Missouri, St. Louis.  Since its inception, DAYA has successfully obtained several SBIR grants from the National Institutes of Health (NIH) and the Department of Energy (DOE).  DAYA is collaborating with many eminent scholars in the academia to advance science and technology.

Raghavan Rajagoplanan, Ph.D., Chief Scientific Officer, Daya Drug Discoveries, Inc.

Doctor of Philosophy, Organic Chemistry, Columbia University, New York, NY
Bachelor of Science, Chemistry, SUNY at Stony Brook, Stony Brook, NY
Graduate Certification, Applied Mathematics, Washington University, St. Louis, MO
Registered Patent Agent, Chemical Arts, United States Patent & Trademark Office

  • Over 30 years of research in organic/medicinal chemistry
  • Over 20 years of patent prosecution/analysis
  • Pioneering discovery in neuropathic pain
  • Pioneering discovery in kidney disease
  • Pioneering discovery in abuse deterrent technology
  • New lead discovery in meth addition and schizophrenia
  • 1 Product in Market, 1 in Phase 1 Clinical, 4 in Pre-clinical, 2 in Proof of Concept stage.
  • 85 Issued Patents
  • 20 Pending Patent Applications
  • 50 Professional publications and presentations